PT-141 (Bremelanotide)
Centrally acting melanocortin agonist - FDA-approved as Vyleesi for HSDD in premenopausal women.
ClinicalFDA-approvedInjectableMelanocortin
Key facts
Common routesSubcutaneous
Half-life~2.7 hours
Typical range1.75 mg on-demand
Summary
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally in the nervous system on MC4R, modulating desire and arousal signaling - not on vasculature like PDE5 inhibitors. As Vyleesi, bremelanotide is FDA-approved for acquired, generalized HSDD (hypoactive sexual desire disorder) in premenopausal women, on-demand 45 minutes before activity.
The central mechanism defines what to expect and what not to: it raises desire but doesn't guarantee an erection, and it carries a real side-effect profile (nausea, flushing, transient BP rise) that limits who should use it.
Mechanism notes
Central MC4R agonism
Activates melanocortin receptors (mainly MC4R) in CNS regions that drive sexual motivation and arousal. This is the difference from PDE5 inhibitors - PT-141 works on the “wanting” signal, not on the vascular response.
Dopaminergic modulation
Melanocortin signaling interacts with dopaminergic arousal circuits; that plausibly explains why users describe it as increased sexual interest rather than a purely mechanical effect.
Dosing patterns
On-demand protocol (approved use)
1.75 mg subcutaneous, at least 45 minutes before anticipated sexual activity. Max 1 dose per 24 hours, max 8 doses per month. Discontinue if no meaningful benefit after ~8 weeks - that's the FDA label's own instruction.
What it is and what it isn't
Expectation setting matters. PT-141 is not a “sex booster” and doesn't replace PDE5 inhibitors. Users expecting a reliable mechanical effect will be disappointed; users with actually low desire are more likely to benefit. Off-label use often pushes past the useful envelope.
Evidence snapshot
The evidence base is strong for one specific indication: two Phase 3 RCTs (RECONNECT program) in premenopausal HSDD showed statistically significant improvements in desire and distress versus placebo. Effect sizes are modest - nausea and discontinuation rates limit real-world persistence. Outside HSDD, the evidence drops off sharply.
Phase 3 / FDA approval
Two Phase 3 RCTs (Kingsberg et al., 2019) support the HSDD approval; the central mechanism is validated by clinical outcomes.
Off-label reality
Response rates vary widely; placebo effects in sexual-function trials are substantial. For ED in men, PDE5 inhibitors remain first-line.
Safety considerations
The risk-benefit is shaped mostly by two things: nausea (dose-limiting, can hit up to 40% of users, often the reason for discontinuation) and transient cardiovascular effects (BP rise, heart-rate drop). Repeated dosing can cause skin or gum hyperpigmentation. In healthy adults the profile is manageable; in uncontrolled hypertension or known CVD it's contraindicated.
Key cautions
- Not a PDE5 inhibitor - increases desire and arousal signaling, doesn't force an erection by itself
- Transient blood pressure rise and heart-rate drop after dosing; contraindicated with uncontrolled hypertension or known CVD
- Nausea is the dose-limiting side effect; stay within max 1 dose/24h and 8 doses/month